Mark W. Hahn

Mark Hahn is a biopharmaceutical executive with over 25 years of leadership experience and scaling life sciences companies. He served as Chief Financial Officer of Verona Pharma from 2020 until its $10 billion acquisition by Merck in 2025, leading the company through pivotal Phase 3 trials, FDA approval, and the launch of Ohtuvayre® for chronic obstructive pulmonary disease. Previously, he was CFO of Dova Pharmaceuticals, acquired by Swedish Orphan Biovitrum for up to $915 million, and CFO of Cempra where he led the company’s IPO and several subsequent follow-on offerings. Prior to Cempra, Mr. Hahn was the CFO of several other public and private companies. Mr. Hahn began his career at Ernst & Young. Mr. Hahn also serves on the Board and as Chair of the Audit Committee of Opterion Health, a privately held clinical-stage biopharmaceutical company. He received a Bachelor of Business Administration degree in Accounting and Finance from the University of Wisconsin-Milwaukee and is a certified public accountant in Maryland and North Carolina (inactive).